fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Cyclosporine Capsules (02495805), Cyclosporine Capsules (02495821), Cyclosporine Capsules (02495813). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Cyclosporine

Form:

10 of 10 products shown

8 general benefit · 2 not a benefit

Neoral · DIN 02237671 · 10 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Special Drugs ProgramSpecial Drugs Program: Cyclosporine for people who have had a solid organ or bone marrow transplant (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Neoral · DIN 02237671 Manufacturer: Novartis Pharma Canada Inc.; listing date 2000-01-17 Health Canada: Marketed since 1998-10-02 · brand NEORAL · ATC L04AD01 CICLOSPORIN · form Capsule · route Oral · ingredients CYCLOSPORINE 10 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Neoral: Formulary list price $0.78 per unit (the source does not state the unit; exact figure $0.7829). What the ministry pays, not the patient.

Ministry pays: $0.7829 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02237671)

Source record
DIN 02237671: Neoral Raw flags: sec3=Y Item: 920000324; group id 907; item number 2170; lccId None; manufacturer id NOV Source form: Cap; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.7829; ministry $0.7829 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02237671 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61016
Shortage status: resolved shortage (ended September 23, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02237671
Shortage record checked October 6, 2026

Neoral · DIN 02150689 · 25 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Special Drugs ProgramSpecial Drugs Program: Cyclosporine for people who have had a solid organ or bone marrow transplant (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Neoral · DIN 02150689 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-12-19 Health Canada: Marketed since 2014-07-12 · brand NEORAL · ATC L04AD01 CICLOSPORIN · form Capsule · route Oral · ingredients CYCLOSPORINE 25 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ministry pays: $0.8657 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02150689)

Source record
DIN 02150689: Neoral Raw flags: sec3=Y Item: 920000166; group id 907; item number 2171; lccId None; manufacturer id NOV Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $1.8207; ministry $0.8657 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02150689 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17813
Interchangeable products
Sandoz Cyclosporine · DIN 02247073 · $0.8657
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02150689
Shortage record checked October 6, 2026

Sandoz Cyclosporine · DIN 02247073 · 25 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Special Drugs ProgramSpecial Drugs Program: Cyclosporine for people who have had a solid organ or bone marrow transplant (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Sandoz Cyclosporine · DIN 02247073 Manufacturer: Sandoz Canada Inc.; listing date 2006-01-24 Health Canada: Marketed since 2006-02-18 · brand SANDOZ CYCLOSPORINE · ATC L04AD01 CICLOSPORIN · form Capsule · route Oral · ingredients CYCLOSPORINE 25 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Cyclosporine: Formulary list price $0.87 per unit (the source does not state the unit; exact figure $0.8657). What the ministry pays, not the patient.

Ministry pays: $0.8657 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02247073)

Source record
DIN 02247073: Sandoz Cyclosporine Raw flags: sec3=Y Item: 920000166; group id 907; item number 2171; lccId None; manufacturer id SDZ Source form: Cap; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.8657; ministry $0.8657 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247073 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71308
Interchangeable products
Neoral · DIN 02150689 · $0.8657
Shortage status: resolved shortage (ended February 16, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247073
Shortage record checked October 6, 2026

Neoral · DIN 02150662 · 50 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Special Drugs ProgramSpecial Drugs Program: Cyclosporine for people who have had a solid organ or bone marrow transplant (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Neoral · DIN 02150662 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-12-19 Health Canada: Marketed since 2014-07-12 · brand NEORAL · ATC L04AD01 CICLOSPORIN · form Capsule · route Oral · ingredients CYCLOSPORINE 50 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ministry pays: $1.6885 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02150662)

Source record
DIN 02150662: Neoral Raw flags: sec3=Y Item: 920000167; group id 907; item number 2172; lccId None; manufacturer id NOV Source form: Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $3.5512; ministry $1.6885 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02150662 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17814
Interchangeable products
Sandoz Cyclosporine · DIN 02247074 · $1.6885
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02150662
Shortage record checked October 6, 2026

Sandoz Cyclosporine · DIN 02247074 · 50 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Special Drugs ProgramSpecial Drugs Program: Cyclosporine for people who have had a solid organ or bone marrow transplant (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Sandoz Cyclosporine · DIN 02247074 Manufacturer: Sandoz Canada Inc.; listing date 2007-01-02 Health Canada: Marketed since 2006-10-18 · brand SANDOZ CYCLOSPORINE · ATC L04AD01 CICLOSPORIN · form Capsule · route Oral · ingredients CYCLOSPORINE 50 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Cyclosporine: Formulary list price $1.69 per unit (the source does not state the unit; exact figure $1.6885). What the ministry pays, not the patient.

Ministry pays: $1.6885 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02247074)

Source record
DIN 02247074: Sandoz Cyclosporine Raw flags: sec3=Y Item: 920000167; group id 907; item number 2172; lccId None; manufacturer id SDZ Source form: Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $1.6885; ministry $1.6885 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247074 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71309
Interchangeable products
Neoral · DIN 02150662 · $1.6885
Shortage status: resolved shortage (ended February 16, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247074
Shortage record checked October 6, 2026

Neoral · DIN 02150670 · 100 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Special Drugs ProgramSpecial Drugs Program: Cyclosporine for people who have had a solid organ or bone marrow transplant (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Neoral · DIN 02150670 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-12-19 Health Canada: Marketed since 2014-07-12 · brand NEORAL · ATC L04AD01 CICLOSPORIN · form Capsule · route Oral · ingredients CYCLOSPORINE 100 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Ministry pays: $3.3792 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02150670)

Source record
DIN 02150670: Neoral Raw flags: sec3=Y Item: 920000169; group id 907; item number 2173; lccId None; manufacturer id NOV Source form: Cap; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $7.1073; ministry $3.3792 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02150670 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17799
Interchangeable products
Sandoz Cyclosporine · DIN 02242821 · $3.3792
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02150670
Shortage record checked October 6, 2026

Sandoz Cyclosporine · DIN 02242821 · 100 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Special Drugs ProgramSpecial Drugs Program: Cyclosporine for people who have had a solid organ or bone marrow transplant (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Sandoz Cyclosporine · DIN 02242821 Manufacturer: Sandoz Canada Inc.; listing date 2003-01-30 Health Canada: Marketed since 2006-02-18 · brand SANDOZ CYCLOSPORINE · ATC L04AD01 CICLOSPORIN · form Capsule · route Oral · ingredients CYCLOSPORINE 100 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Cyclosporine: Formulary list price $3.38 per unit (the source does not state the unit; exact figure $3.3792). What the ministry pays, not the patient.

Ministry pays: $3.3792 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02242821)

Source record
DIN 02242821: Sandoz Cyclosporine Raw flags: sec3=Y Item: 920000169; group id 907; item number 2173; lccId None; manufacturer id SDZ Source form: Cap; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $3.3792; ministry $3.3792 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242821 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66649
Interchangeable products
Neoral · DIN 02150670 · $3.3792
Shortage status: active shortage (reported November 10, 2025, estimated to end March 31, 2028, last updated September 14, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242821
Shortage record checked October 6, 2026

Neoral · DIN 02150697 · 100 mg/mL · oral liquid

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Special Drugs ProgramSpecial Drugs Program: Cyclosporine for people who have had a solid organ or bone marrow transplant (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Neoral · DIN 02150697 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-12-19 Health Canada: Marketed since 2014-07-12 · brand NEORAL · ATC L04AD01 CICLOSPORIN · form Solution · route Oral · ingredients CYCLOSPORINE 100 MG/ML · company Novartis pharmaceuticals canada inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Neoral: Formulary list price $6.32 per unit (the source does not state the unit; exact figure $6.3191). What the ministry pays, not the patient.

Ministry pays: $6.3191 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02150697)

Source record
DIN 02150697: Neoral Raw flags: sec3=Y Item: 920000168; group id 907; item number 2174; lccId None; manufacturer id NOV Source form: O/L; strength: 100mg/mL Recorded listing: General benefit Source prices (unrounded): $6.3191; ministry $6.3191 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02150697 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17801
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02150697
Shortage record checked October 6, 2026

Restasis · DIN 02355655 · 0.05% w/v · Oph Emuls-0.4mL Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Special Drugs ProgramSpecial Drugs Program: Cyclosporine for people who have had a solid organ or bone marrow transplant (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Savings card: innoviCares lists Restasis (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Restasis · DIN 02355655 Manufacturer: Allergan Inc.; listing date 2018-01-31 Health Canada: Marketed since 2024-02-05 · brand RESTASIS · ATC S01XA18 CICLOSPORIN · form Emulsion · route Ophthalmic · ingredients CYCLOSPORINE 0.05 %/W/V · company Abbvie corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Restasis: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02355655)

Source record
DIN 02355655: Restasis Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 520892001; group id 602; item number 1562; lccId None; manufacturer id ALL Source form: Oph Emuls-0.4mL Pk; strength: 0.05% w/v Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02355655 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84087
Interchangeable products
Teva-Cyclosporine · DIN 02462486 · not recorded
Shortage status: resolved shortage (ended January 26, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02355655
Shortage record checked October 6, 2026

Teva-Cyclosporine · DIN 02462486 · 0.05% w/v · Oph Emuls-0.4mL Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Special Drugs ProgramSpecial Drugs Program: Cyclosporine for people who have had a solid organ or bone marrow transplant (ontario.ca, Updated 2023-07-13 ↗) Through the Special Drugs Program, the Ministry of Health covers the full cost of certain outpatient drugs used in the treatment of specific conditions. (ontario.ca, Updated 2023-07-13 ↗) The Special Drugs Program will cover costs for the above drugs if the patient: is an Ontario resident has a valid Ontario Health Insurance (OHIP) has one of the diseases or conditions covered meets the established clinical criteria is under the care of an approved physician/designated care centre (ontario.ca, Updated 2023-07-13 ↗)
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Cyclosporine · DIN 02462486 Manufacturer: Teva Canada Limited; listing date 2018-01-31 Health Canada: Marketed since 2017-12-04 · brand TEVA-CYCLOSPORINE · ATC S01XA18 CICLOSPORIN · form Emulsion · route Ophthalmic · ingredients CYCLOSPORINE 0.05 %/W/V · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02462486)

Source record
DIN 02462486: Teva-Cyclosporine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 520892001; group id 602; item number 1562; lccId None; manufacturer id TEV Source form: Oph Emuls-0.4mL Pk; strength: 0.05% w/v Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $4.1658; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02462486 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95023
Interchangeable products
Restasis · DIN 02355655 · not recorded
Shortage status: resolved shortage (ended August 19, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02462486
Shortage record checked October 6, 2026

Other products in the same Health Canada class (L04A, L04AD): coverage varies; not interchangeable

  • Tacrolimus (Prograf): limited Use 173, limited Use 383, limited Use 410, limited Use 590
  • Azathioprine (Imuran): general benefit
  • Leflunomide (Arava): general benefit
  • Mycophenolate mofetil (CellCept): general benefit, limited Use 556
  • Mycophenolate (Myfortic): general benefit
  • Adalimumab (Hyrimoz): limited Use 600, 601, 602, 603, 604, 605, 606, 607, 609, 611, limited Use 600, 602, 603, 604, 605, 606, 607, 609, 633, 634

15 more in the class list below

Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (52:08:92 Anti-Inflammatory Agents, Miscellaneous) and how they are covered

No products matched this class search: “52:08:92”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 52:04:04 Antibiotics, 52:04:12 Other Anti-Infectives

Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

TACROLIMUS

· 20 products · Limited Use, codes 173 (10), Limited Use, codes 410 (8), Limited Use, codes 383 (2) · strengths: 5mg/mL, 0.5mg, 1mg, 5mg, 3mg, 0.03%, 0.1% · Amp, Cap, ER Cap, Oint

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

MYCOPHENOLATE MOFETIL

· 16 products · General benefit (14), Limited Use, codes 556 (2) · strengths: 250mg, 200mg/mL, 500mg · Cap, Pd for Oral Susp-175mL Pk, Tab

MYCOPHENOLATE SODIUM

· 8 products · General benefit · strengths: 180mg, 360mg · Ent Tab

LENALIDOMIDE

· 42 products · Limited Use, codes 630, 631, 632, 659, 741 · strengths: 2.5mg, 15mg, 20mg, 25mg, 5mg, 10mg · Cap

SIROLIMUS

· 2 products · Limited Use, codes 392 · strengths: 1mg/mL, 1mg · O/L, Tab

TERIFLUNOMIDE

· 10 products · Listed, not a benefit (1), Limited Use, codes 647 (9) · strengths: 14mg · Tab

USTEKINUMAB

· 17 products · Limited Use, codes 669, 670, 671, 672 (5), Limited Use, codes 669, 671, 672, 742 (4), Limited Use, codes 668, 669, 671, 672 (2), Limited Use, codes 669, 671, 672, 733 (3), Limited Use, codes 671, 672 (3) · strengths: 45mg/0.5mL, 90mg/1.0mL, 90mg/mL, 130mg/26mL, 5mg/mL · Inj Sol-0.5mL Pref Autoinj (Preservative-Free), Inj Sol-0.5mL Pref Syr (Preservative-Free), Inj Sol-0.5mL Pref Syr Pk, Inj Sol-0.5mL Pref Syr Pk (Preservative-Free), Inj Sol-0.5mL Vial Pk, Inj Sol-1.0mL Pref Syr Pk (Preservative-Free), Inj Sol-1mL Pref Autoinj (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free), Inj Sol-1mL Pref Syr Pk, Inj Sol-26mL Vial Pk, Inj Sol-26mL Vial Pk (Preservative-Free), Inj Sol-Vial Pk (Preservative-Free)

FINGOLIMOD

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (9), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 0.5mg · Cap

PIRFENIDONE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 267mg · Cap

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: active rheumatoid arthritis, psoriasis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ACITRETIN, LEFLUNOMIDE, PENICILLAMINE ACITRETIN · General benefit 1 INDICATIONS SORIATANE (acitretin) is indicated for: • Severe psoriasis (includes erythrodermic and pustular types) • Other disorders of keratinization Severe psoriasis is a condition that involves more than 10% of body surface area or is physically, occupationally or psychologically disabling. PM: https://pdf.hres.ca/dpd_pm/00080165.PDF; date APR 04, 2025; DIN 02070847; fetched 2026-09-10 Product monograph APREMILAST · Off-Formulary Interchangeable, not an ODB benefit Indications • Plaque Psoriasis OTEZLA (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. PM: https://pdf.hres.ca/dpd_pm/00084256.PDF; date 2026-04-10; DIN 02434318; fetched 2026-09-10 Product monograph BIMEKIZUMAB · Limited Use, codes 641 Indications Bimzelx (bimekizumab injection) is indicated for: • Psoriasis (PsO) The treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. PM: https://pdf.hres.ca/dpd_pm/00082779.PDF; date 2025-12-12; DIN 02525267; fetched 2026-09-10 Product monograph • Psoriasis (PsO) The treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. PM: https://pdf.hres.ca/dpd_pm/00082779.PDF; date 2025-12-12; DIN 02525267; fetched 2026-09-10 Product monograph ETANERCEPT · Limited Use, codes 512, 513, 514, 563, 591 (3), Limited Use, codes 498, 499, 514, 563, 591 (4) • treatment of adult patients with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. PM: https://pdf.hres.ca/dpd_pm/00083562.PDF; date August 31, 2016; DIN 02455323; fetched 2026-09-10 Product monograph INFLIXIMAB · Limited Use, codes 468, 469, 470, 471, 477, 478, 479 (2), Limited Use, codes 541, 542, 543, 544, 545, 546, 547 (1), Limited Use, codes 715, 716, 718 (2), Limited Use, codes 592, 593, 594, 595, 596, 597, 598 (1) • treatment of adult patients with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy. For patients with chronic moderate plaque psoriasis, RemdantryTM should be used after phototherapy has been shown to be ineffective or inappropriate. When assessing the severity of psoriasis, the health professional should consider the extent of involvement, location of lesions, response to previous treatments, and impact of disease on the patient’s PM: https://pdf.hres.ca/dpd_pm/00081840.PDF; date September 2, 2025; DIN 02419475; fetched 2026-09-10 Product monograph LEFLUNOMIDE · General benefit ARAVA is indicated in adults for the treatment of active rheumatoid arthritis. 1.1 Pediatrics The use in patients less than 18 years of age is contraindicated. 1.2 Geriatrics No dosage adjustment is needed in patients over 65 years of age. PM: https://pdf.hres.ca/dpd_pm/00083555.PDF; date not captured; DIN 02241888; fetched 2026-09-10 Product monograph METHOTREXATE · General benefit (29), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (4) • Severe disabling psoriasis/psoriatic arthritis PM: https://pdf.hres.ca/dpd_pm/00078227.PDF; date JAN 08, 2025; DIN 02170698; fetched 2026-09-10 Product monograph PENICILLAMINE · General benefit INDICATIONS AND CLINICAL USE CUPRIMINE (penicillamine capsules, USP) is indicated for:  treatment of Wilson's disease  chronic lead poisoning  cystinuria, and  In patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. PM: https://pdf.hres.ca/dpd_pm/00054287.PDF; date not captured; DIN 00016055; fetched 2026-09-10 Product monograph RISANKIZUMAB · Limited Use, codes 574 Indications SKYRIZI (risankizumab injection) is indicated for: • the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. PM: https://pdf.hres.ca/dpd_pm/00085642.PDF; date 2026-07-08; DIN 02519283; fetched 2026-09-10 Product monograph SECUKINUMAB · Limited Use, codes 476 Indications COSENTYX® (secukinumab injection/secukinumab for injection) is indicated for: Adult patients Plaque psoriasis COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. PM: https://pdf.hres.ca/dpd_pm/00080972.PDF; date not captured; DIN 02529653; fetched 2026-09-10 Product monograph Hidradenitis Suppurativa COSENTYX is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa (acne inversa) who have responded inadequately to conventional systemic hidradenitis suppurativa therapy (see 14.1.5 Hidradenitis suppurativa). 1.1 Pediatrics Plaque psoriasis COSENTYX (secukinumab injection/secukinumab for injection) is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 year and older who are candidates for systemic therapy or phototherapy. PM: https://pdf.hres.ca/dpd_pm/00080972.PDF; date not captured; DIN 02529653; fetched 2026-09-10 Product monograph and 3 more Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1. Indications Solid Organ Transplantation NEORAL® capsules and oral solution and SANDIMMUNE I.V.® (cyclosporine) are indicated in the prevention of graft rejection following solid organ transplantation and in the treatment of transplant rejection in patients previously receiving other immunosuppressive agents. Bone Marrow Transplantation NEORAL capsules and oral solution and SANDIMMUNE I.V. (cyclosporine) are indicated in the prevention of graft rejection following bone marrow transplantation and the prevention or treatment of graft- versus-host disease (GVHD). Psoriasis NEORAL capsules and oral solution (cyclosporine) are indicated for the treatment of severe psoriasis in patients for whom conventional therapy is ineffective or inappropriate. Rheumatoid Arthritis NEORAL capsules and oral solution (cyclosporine) are also indicated for the treatment of severe active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents are inappropriate or ineffective. Nephrotic Syndrome NEORAL capsules and oral solution (cyclosporine) are indicated in adults and children for steroid dependent and steroid resistant nephrotic syndrome due to glomerular dise… https://pdf.hres.ca/dpd_pm/00085584.PDF PM date: 2026-07-30 Source product: NEORAL; DIN 02150662; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Sandoz Cyclosporine · DIN 02242821 Shortage status: active shortage (reported 2025-11-10, estimated to end 2028-03-31, last updated 2026-09-14); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242821

Check this DIN again

Other review policies

For Restasis, Teva-Cyclosporine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026